The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

Kura will see more combo data, while a new contender from Sumitomo emerges.

The company abandons TNG908, but is still all in on the troubled target.

After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.

Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

The company reckons it’s got what it takes to hit the right member of the FGFR family.